Funding for this research was provided by:
CIHR (PJT-156302, FND-154286)
University of British Columbia (4 year fellowship)
Article History
Received: 17 March 2020
Accepted: 28 May 2020
First Online: 16 June 2020
Ethics approval and consent to participate
: Animal experiments were carried out in accordance with the Canadian Council of Animal Care and with the approval of the Animal Care Committee at the University of British Columbia.
: Not applicable.
: Y.T.W. and A.G.P. declare a patent related to glutamate receptor function (A Peptide that Specifically Blocks Regulated AMPA Receptor Endocytosis and Hippocampal CA1 Long-term Depression; European 04789721.0, and United States 13/066,700). A.G.P. also declares a patent related to the use of d-govadine to enhance dopamine function in the prefrontal cortex. Authors report no other biomedical financial interests or potential conflicts of interest.